» Articles » PMID: 17496922

MAP Kinase Signalling Pathways in Cancer

Overview
Journal Oncogene
Date 2007 May 15
PMID 17496922
Citations 1346
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer can be perceived as a disease of communication between and within cells. The aberrations are pleiotropic, but mitogen-activated protein kinase (MAPK) pathways feature prominently. Here, we discuss recent findings and hypotheses on the role of MAPK pathways in cancer. Cancerous mutations in MAPK pathways are frequently mostly affecting Ras and B-Raf in the extracellular signal-regulated kinase pathway. Stress-activated pathways, such as Jun N-terminal kinase and p38, largely seem to counteract malignant transformation. The balance and integration between these signals may widely vary in different tumours, but are important for the outcome and the sensitivity to drug therapy.

Citing Articles

Revolutionary Cancer Therapy for Personalization and Improved Efficacy: Strategies to Overcome Resistance to Immune Checkpoint Inhibitor Therapy.

Almawash S Cancers (Basel). 2025; 17(5).

PMID: 40075727 PMC: 11899125. DOI: 10.3390/cancers17050880.


Semaglutide, a glucagon-like peptide-1 receptor agonist, inhibits oral squamous cell carcinoma growth through P38 MAPK signaling pathway.

Wang C, Wu Z, Zhou J, Cheng B, Huang Y J Cancer Res Clin Oncol. 2025; 151(3):103.

PMID: 40055197 PMC: 11889073. DOI: 10.1007/s00432-025-06154-5.


Transcriptomics insights into glutamine on repairing of histamine-induced Yak rumen epithelial cells barrier damage in vitro.

Zhang X, Hu R, Wang Z, Wang J, Yue Z, Wu F BMC Genomics. 2025; 26(1):195.

PMID: 40000997 PMC: 11863408. DOI: 10.1186/s12864-025-11383-6.


TM7SF2 as a Potential Biomarker in Colorectal Cancer: Implications for Metastasis.

Hong I, Kim S, Lee M, Han S, Kim H, Chu C Curr Oncol. 2025; 32(2).

PMID: 39996914 PMC: 11854686. DOI: 10.3390/curroncol32020114.


Overexpression of FOS enhances the malignant potential of eutopic endometrial stromal cells in patients with endometriosis‑associated ovarian cancer.

Chen J, He K, Li X, Wang M, Yang Z, Wang Z Oncol Rep. 2025; 53(4).

PMID: 39981914 PMC: 11851058. DOI: 10.3892/or.2025.8878.